In vitro metabolic fate of the synthetic cannabinoid receptor agonists (quinolin-8-yl 4-methyl-3-(morpholine-4-sulfonyl)benzoate [QMMSB]) and (quinolin-8-yl 4-methyl-3-((propan-2-yl)sulfamoyl)benzoate [QMiPSB]) including isozyme mapping and carboxylesterases activity testing.
carboxylesterases
metabolism
monooxygenases
new psychoactive substances
synthetic cannabinoid receptor agonists
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
06
10
2022
received:
04
09
2022
accepted:
10
10
2022
pubmed:
15
10
2022
medline:
14
2
2023
entrez:
14
10
2022
Statut:
ppublish
Résumé
The synthetic cannabinoid receptor agonists (SCRAs) (quinolin-8-yl 4-methyl-3-(morpholine-4-sulfonyl)benzoate [QMMSB]) and (quinolin-8-yl 4-methyl-3-((propan-2-yl)sulfamoyl)benzoate [QMiPSB], also known as SGT-46) are based on the structure of quinolin-8-yl 4-methyl-3-(piperidine-1-sulfonyl)benzoate (QMPSB) that has been identified on seized plant material in 2011. In clinical toxicology, knowledge of the metabolic fate is important for their identification in biosamples. Therefore, the aim of this study was the identification of in vitro Phase I and II metabolites of QMMSB and QMiPSB in pooled human liver S9 fraction (pHLS9) incubations for use as screening targets. In addition, the involvement of human monooxygenases and human carboxylesterases (hCES) was examined. Analyses were performed by liquid chromatography coupled with high-resolution tandem mass spectrometry. Ester hydrolysis was found to be an important step in the Phase I metabolism of both SCRAs, with the carboxylic acid product being found only in negative ionization mode. Monohydroxy and N-dealkyl metabolites of the ester hydrolysis products were detected as well as glucuronides. CYP2C8, CYP2C9, CYP3A4, and CYP3A5 were involved in hydroxylation. Whereas enzymatic ester hydrolysis of QMiPSB was mainly catalyzed by hCES1 isoforms, nonenzymatic ester hydrolysis was also observed. The results suggest that ester hydrolysis products of QMMSB and QMiPSB and their glucuronides are suitable targets for toxicological screenings. The additional use of the negative ionization mode is recommended to increase detectability of analytes. Different cytochrome P450 (CYP) isozymes were involved in the metabolism; thus, the probability of drug-drug interactions due to CYP inhibition can be assessed as low.
Substances chimiques
Cannabinoid Receptor Agonists
0
Benzoates
0
Isoenzymes
0
Glucuronides
0
Cytochrome P-450 Enzyme System
9035-51-2
Morpholines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-191Informations de copyright
© 2022 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
UNODC. World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_2.pdf. Accessed August 11, 2022.
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1-13. doi:10.3109/15563650.2015.1110590
EMCDDA. European Drug Report 2022 - Trends and Developments. 2022. https://www.emcdda.europa.eu/system/files/publications/14644/TDAT22001ENN.pdf. Accessed August 11, 2022.
EMCDDA. Perspectives on drugs, Synthetic cannabinoids in Europe. 2017. https://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdf. Accessed August 11, 2022.
Lambeng N, Lebon F, Christophe B, Burton M, De Ryck M, Quere L. Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies. Bioorg Med Chem Lett. 2007;17(1):272-277. doi:10.1016/j.bmcl.2006.09.049
Ermann M, Riether D, Walker ER, et al. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. Bioorg Med Chem Lett. 2008;18(5):1725-1729. doi:10.1016/j.bmcl.2008.01.042
Brandt SD, Kavanagh PV, Westphal F, et al. Synthetic cannabinoid receptor agonists: analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233. Drug Test Anal. 2021;13(1):175-196. doi:10.1002/dta.2913
Blakey K, Boyd S, Atkinson S, et al. Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense. Forensic Sci Int. 2016;260:40-53. doi:10.1016/j.forsciint.2015.12.001
Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C. Identification and analytical characterization of a novel synthetic cannabinoid-type substance in herbal material in Europe. Molecules. 2021;26(4):793. doi:10.3390/molecules26040793
Uchiyama N, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 2013;31(2):223-240. doi:10.1007/s11419-013-0182-9
Wagmann L, Maurer HH. Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol. 2018;252:413-439. doi:10.1007/164_2017_83
Richter MJ, Wagmann L, Gampfer TM, Brandt SD, Meyer MR. In vitro metabolic fate of the synthetic cannabinoid receptor agonists QMPSB and QMPCB (SGT-11) including isozyme mapping and esterase activity. Metabolites. 2021;11(8):509. doi:10.3390/metabo11080509
Richter MJ, Wagmann L, Brandt SD, Meyer MR. In vitro metabolic fate of the synthetic cannabinoid receptor agonists 2F-QMPSB and SGT-233 including isozyme mapping and carboxylesterases activity testing. J Anal Toxicol. 2022;1-9. doi:10.1093/jat/bkac072
Richter LHJ, Flockerzi V, Maurer HH, Meyer MR. Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. J Pharm Biomed Anal. 2017;143:32-42. doi:10.1016/j.jpba.2017.05.028
Wagmann L, Meyer MR, Maurer HH. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett. 2016;258:55-70. doi:10.1016/j.toxlet.2016.06.013
Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs. Anal Chim Acta. 2015;891:221-233. doi:10.1016/j.aca.2015.08.018
Wagmann L, Manier SK, Felske C, et al. Flubromazolam-derived designer benzodiazepines: Toxicokinetics and analytical toxicology of Clobromazolam and Bromazolam. J Anal Toxicol. 2021;45(9):1014-1027. doi:10.1093/jat/bkaa161
Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA. In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS j. 2016;18(2):455-464. doi:10.1208/s12248-016-9867-4
Holsztynska EJ, Domino EF. Biotransformation of phencyclidine. Drug Metab Rev. 1985;16(3):285-320. doi:10.3109/03602538508991437
Michely JA, Manier SK, Caspar AT, Brandt SD, Wallach J, Maurer HH. New psychoactive substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): metabolic fate elucidated with rat urine and human liver preparations and their detectability in urine by GC-MS, “LC-(high resolution)-MSn” and “LC-(high resolution)-MS/MS”. Curr Neuropharmacol. 2017;15(5):692-712. doi:10.2174/1570159X14666161018151716
Meyer MR, Schutz A, Maurer HH. Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett. 2015;232(1):159-166. doi:10.1016/j.toxlet.2014.10.026
Thomsen R, Rasmussen HB, Linnet K, The INDICES Consortium. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos. 2014;42(1):126-133. doi:10.1124/dmd.113.053512
Wang J, Williams ET, Bourgea J, Wong YN, Patten CJ. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug Metab Dispos. 2011;39(8):1329-1333. doi:10.1124/dmd.111.039628
Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20(2):91-102. doi:10.2174/1389200219666180821094502
Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K, the INDICES Consortium. Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. 2015;7(7):565-576. doi:10.1002/dta.1731
Wagmann L, Stiller RG, Fischmann S, Westphal F, Meyer MR. Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases. Arch Toxicol. 2022;96(10):2755-2766. doi:10.1007/s00204-022-03332-z